Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria
Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria have?
Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria has 65 citations in the OpenAlex counts ScholarIQ stores.
When was Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria published?
Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria has 2018 year in the ScholarIQ index.
What is the open-access status of Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?
Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria has closed oa status in the ScholarIQ index.
What is the DOI of Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?
The DOI for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is on the source record.
What is the PMID of Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?
The PMID for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is on the source record.
What is the OpenAlex record for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria?
The OpenAlex for Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria is on the source record.